Contents

Interstitital Lung DiseaseEdit

Interstitial lung disease (ILD) is a broad and heterogeneous group of disorders characterized by inflammation and fibrosis of the lung interstitium, the thin walls surrounding the air sacs. This process can impair gas exchange and lead to progressive shortness of breath and cough. ILD includes idiopathic diseases as well as those related to environmental exposures, autoimmune conditions, infections, and certain medications. Because the causes and patterns of injury vary, a careful, multidisciplinary approach is essential to diagnosis and management. See for example interstitial lung disease for the general background, Idiopathic pulmonary fibrosis for the most common fibrosing form, and hypersensitivity pneumonitis for exposure-driven disease.

The field emphasizes balancing early, accurate diagnosis with practical considerations of treatment risk, cost, and access to care. In many health systems, decisions about testing and therapies are shaped by patient age, comorbidities, occupational exposures, and the availability of specialist pulmonary care. This article surveys the major disease groups, diagnostic pathways, and treatment options, while noting ongoing debates about cost, access, and policy implications that influence patient outcomes.

Epidemiology

ILD as a group affects adults worldwide, with incidence and prevalence that vary by region and population. Idiopathic forms tend to present in middle to older age, though some environmental or autoimmune-related ILDs can appear earlier. Overall, the burden of disease is substantial due to chronic symptoms, reduced quality of life, and the potential need for long-term oxygen therapy or transplantation. Data on race and ethnicity show different patterns of risk across populations, and researchers continue to study how genetic and environmental factors intersect with social determinants of health. In terms of race, discussions of risk and outcomes should be approached with precision and respect for individuals, noting that findings are epidemiological rather than prescriptive. See racial and ethnic health disparities for related context.

Etiology and classification

ILD encompasses numerous etiologies, which can be broadly categorized as idiopathic, exposure-related, autoimmune or connective tissue disease–related, drug-induced, and granulomatous or other miscellaneous causes.

  • Idiopathic interstitial pneumonias (IIPs) include the most prominent fibrosing form, Idiopathic pulmonary fibrosis (IPF). IPF is characterized by a UIP (usual interstitial pneumonia) pattern on imaging and has a prognosis that ranges from indolent to progressive. See Idiopathic pulmonary fibrosis.

  • Hypersensitivity pneumonitis (HP) arises from immune responses to inhaled antigens such as mold, bird proteins, or other organic materials. HP can be acute, subacute, or chronic and may mimic IPF on imaging and symptoms. See Hypersensitivity pneumonitis.

  • Autoimmune or connective tissue disease–associated ILD (CTD-ILD) occurs when the interstitial lung disease is part of an autoimmune process, for example systemic sclerosis or rheumatoid arthritis–associated ILD.

  • Occupational and environmental exposures include pneumoconioses (such as asbestosis and silicosis) and other inhalational injuries. Management often requires removal from exposure and supportive care.

  • Drug-induced ILD results from reactions to certain medications (for example, some chemotherapeutics, amiodarone, or methotrexate) and can improve with drug withdrawal in many cases.

  • Other ILDs include non-specific interstitial pneumonia (NSIP), pleuroparenchymal fibroelastosis, and granulomatous diseases. See non-specific interstitial pneumonia and pleuroparenchymal fibroelastosis for related conditions.

Genetic factors contribute to susceptibility in some patients. Variants in genes related to telomere maintenance and the MUC5B promoter have been associated with increased risk of fibrosis and slower or faster disease progression in certain ILDs. See MUC5B promoter variant and telomere biology disorders for context.

Pathophysiology

Interstitium thickening from inflammation and subsequent fibrosis disrupts the architecture of the distal airways and alveoli, reducing lung compliance and diffusion capacity. In IPF and many fibrosing ILDs, a cyclical injury–repair process leads to abnormal scarring, architectural distortion, and honeycombing in advanced disease. In HP and CTD-ILD, ongoing immune-mediated injury and inflammation can both trigger and sustain the fibrotic process. The net effect is impaired oxygen transfer, exertional dyspnea, and, over time, progressive limitation in activity.

Clinical features and diagnosis

Clinical presentation commonly includes progressive shortness of breath on exertion and a nonproductive cough. Exam findings may include velcro-like inspiratory crackles and, in some cases, clubbing of the fingers. The course varies by disease type and individual factors such as age and comorbidity.

Diagnostic evaluation relies on a multidisciplinary approach, integrating: - History of exposures (occupational or environmental) and autoimmune symptoms. - High-resolution computed tomography (HRCT) to identify patterns such as UIP or NSIP. - Pulmonary function testing (pulmonary function test) showing a restrictive pattern with reduced diffusing capacity for carbon monoxide (DLCO). - Serologic testing for autoimmune disease when indicated. - In some cases, bronchoscopy with bronchoalveolar lavage or, less commonly, lung biopsy to achieve a definitive diagnosis.

A key component of diagnosis is multidisciplinary discussion among pulmonologists, radiologists, and pathologists to determine the closest ILD category and best management plan. See high-resolution computed tomography and bronchoscopy for related procedures and terms.

Management

Management centers on slowing disease progression, relieving symptoms, preventing complications, and maintaining quality of life. Approaches include:

  • Nonpharmacologic care: vaccination (influenza, pneumococcus, and others as recommended), smoking cessation, pulmonary rehabilitation, and optimized management of comorbidities (heart disease, gastroesophageal reflux, sleep apnea). Oxygen therapy is indicated for hypoxemia, and pulmonary rehabilitation helps maintain exercise tolerance.

  • Pharmacologic therapy:

    • Antifibrotic agents (e.g., pirfenidone, nintedanib) slow the rate of decline in many fibrosing ILDs, particularly IPF, and are used in a range of progressive fibrosing ILDs under physician judgment. See pirfenidone and nintedanib.
    • Immunosuppressive or anti-inflammatory therapies are used selectively. Corticosteroids may be helpful in HP and certain CTD-ILD but are generally less beneficial in IPF; treatment must be tailored to the underlying etiology.
    • Drug withdrawal is appropriate for drug-induced ILD when feasible, and alternative therapies should be considered.

  • Advanced care and transplantation: For suitable patients, lung transplantation may be discussed as a potential option when disease progresses despite optimal therapy.

  • Clinical trials: Ongoing research into novel anti-fibrotic strategies, anti-inflammatory approaches, and regenerative therapies continues to evolve the treatment landscape. See clinical trial for context.

Controversies and debates

ILD care sits at the intersection of medicine, economics, and policy, which gives rise to several debates:

  • Cost and access to antifibrotic drugs: Pirfenidone and nintedanib can be expensive, raising questions about payer coverage, patient affordability, and the balance between extending life and the financial burden on families and health systems. Advocates point to slowed disease progression and improved quality of life; critics highlight access disparities and rising overall health care costs.

  • Environmental exposure regulation vs. economic impact: Reducing exposure to inhalational antigens (in workplaces or living environments) may reduce disease incidence or progression, but such measures can entail compliance costs for employers and property owners. Supporters argue that prevention yields long-term savings and healthier populations; opponents worry about regulatory burdens.

  • Diagnostic standardization and the role of multidisciplinary teams: While a multidisciplinary approach improves diagnostic accuracy, it also requires access to specialized centers, which may not be available in all regions. Proponents highlight better outcomes with MDT (multidisciplinary team) review; critics worry about delays and resource constraints.

  • Emphasis on social determinants of health and equity: From a broader policy perspective, discussions about access, disparities, and equity influence ILD care delivery. Proponents contend that equity improves outcomes and aligns with clinical ethics; critics of certain framing argue that resource constraints should prioritize proven, patient-centered medical interventions. From a practical, value-driven standpoint, the focus is on maximizing patient survival, symptom relief, and cost-effective care. Some critics argue that certain social-justice framing can distract from rapid, evidence-based medical decisions; supporters counter that equity and access are integral to optimal outcomes, not a separate concern. The core point is to pursue policies that expand effective therapies, streamline diagnosis, and prevent disease where possible, while avoiding unnecessary costs or bureaucratic barriers.

  • Representation in trials and real-world applicability: Ensuring diverse populations participate in trials improves generalizability, but some argue it can complicate trial design and interpretation. Balancing representativeness with study power remains an ongoing consideration for researchers and funders.

See also